All News

    Ivonescimab Plus Chemo Delays NSCLC Progression

    September 8th 2025, 7:00pm

    Article

    In patients with EGFR-mutated NSCLC ivonescimab plus chemotherapy was associated with significant progression-free survival.

    Standing Up to Cancer on My Own Two Feet

    September 8th 2025, 5:00pm

    Article

    Thoughts on standing up to cancer through recovered mobility and by sharing my multiple myeloma journey.

    FLAURA2 Shows Tagrisso Plus Chemo Boosts Survival in EGFR+ Lung Cancer

    September 8th 2025, 4:00pm

    Video

    Dr. Eric Singhi sat down with CURE to break down the findings from the phase 3 FLAURA2 study, presented at the 2025 IASLC World Conference on Lung Cancer.

    FDA Grants Orphan Drug Designation to BA-101 in Glioblastoma

    September 8th 2025, 3:02pm

    Article

    The FDA has granted orphan drug designation to the investigational therapy BA-101 for the treatment of patients with glioblastoma.

    Ifinatamab Deruxtecan Shows Activity in Previously Treated ES-SCLC

    September 8th 2025, 1:17pm

    Video

    Dr. Myung-Ju Ahn shared notable data on ifinatamab deruxtecan for patients with previously treated extensive-stage small cell lung cancer.

    Tagrisso With Chemotherapy Improves Survival in EGFR+ NSCLC

    September 7th 2025, 6:00pm

    Article

    People with EGFR+ NSCLC whose disease spread outside the brain after treatment with Tagrisso lived longer when they kept taking Tagrisso along with chemo.

    Iza-bren Plus Tagrisso May Offer a New Option for Advanced Lung Cancer

    September 7th 2025, 2:00pm

    Article

    A combination of Iza-bren and Tagrisso showed beneficial results as an initial treatment for advanced/metastatic EGFR-mutated non–small cell lung cancer.

    Dispelling Myths and Raising Awareness of Lung Cancer Risk

    September 6th 2025, 6:00pm

    Video

    Never-smoker Leah Phillips, co-founder of the Young Lung Cancer Initiative, raises awareness that anyone with lungs can develop lung cancer.

    Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma

    September 6th 2025, 2:00pm

    Article

    Data from the AQUILA study support the use of fixed-duration subcutaneous Darzalex Faspro as an early treatment option in high-risk smoldering myeloma.

    Venclexta And Azacitidine Fail to Improve MDS Survival

    September 5th 2025, 9:00pm

    Article

    Results from the phase 3 VERONA trial were presented at the 2025 Society of Hematologic Oncology Annual Meeting.